Study Reinforces BRAF-MEK Inhibition Over Anti-BRAF Only in Advanced Melanoma
MedPage Today,
Oncology/Hematology > Skin Cancer Improved PFS with encorafenib-binimetinib versus encorafenib, but immunotherapy still top…
Oncology/Hematology > Skin Cancer Improved PFS with encorafenib-binimetinib versus encorafenib, but immunotherapy still top…
Melanoma treatment has progressed dramatically in the past decade. For patients with BRAF V600–mutated disease, immunotherapy…
Oncology > Skin Cancer Encorafenib-binimetinib tops vemurafenib, but checkpoint inhibitors remain first-line choice by Charles…
Watch for alopecia, arthralgia, diarrhea, fatigue, nausea, pyrexia, rash, and vomiting, among others.